Healthcare ❯ Regulatory Affairs ❯ Drug Approval Process ❯ FDA Designations

Breakthrough Therapy Designation

Amylyx’s Avexitide Cuts Moderate‑to‑Severe Post‑Bariatric Hypoglycemia Events 55% in Phase 3

Amylyx plans a year‑end FDA filing that could lead to a 2027 launch funded by a new equity offering.